{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:21:23Z","timestamp":1791469283012,"version":"4.3.4"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treatment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, therapeutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.<\/jats:p>","DOI":"10.1007\/s44313-025-00055-9","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T13:58:17Z","timestamp":1738677497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions"],"prefix":"10.1007","volume":"60","author":[{"given":"Sung-Hoon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Moon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Ri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeung-Chul","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Mee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Young","family":"Yhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Hwan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Han","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"18","key":"55_CR1","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1056\/NEJMra041875","volume":"351","author":"RA Kyle","year":"2004","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860\u201373.","journal-title":"N Engl J Med"},{"issue":"2","key":"55_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4143\/crt.2024.253","volume":"56","author":"EH Park","year":"2024","unstructured":"Park EH, Jung KW, Park NJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2021. Cancer Res Treat. 2024;56(2):357\u201371.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"55_CR3","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302\u201312.","journal-title":"Lancet Oncol"},{"issue":"2","key":"55_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","volume":"16","author":"L Bertamini","year":"2021","unstructured":"Bertamini L, D\u2019Agostino M, Gay F. MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep. 2021;16(2):162\u201371.","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"55_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, Version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281\u2013301.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"55_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020). Ann Oncol. 2021;32(3):309\u201322.","journal-title":"Ann Oncol"},{"issue":"3","key":"55_CR7","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105\u201318.","journal-title":"Lancet Oncol"},{"key":"55_CR8","unstructured":"Cochrance. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrance;c2019. Available from: https:\/\/trainingcochrane.org\/hand.\u00a0Cited 2019 Aug 25."},{"key":"55_CR9","unstructured":"Sch\u00fcnemann H BJ, Guyatt G, Oxman A. Oxman A. GRADE Handbook. London: Cochrane Collaboration; c2013. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html.\u00a0Cited 2019 Aug 25."},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"issue":"10192","key":"55_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338.","journal-title":"Lancet"},{"issue":"1","key":"55_CR12","doi-asserted-by":"publisher","first-page":"e1003454","DOI":"10.1371\/journal.pmed.1003454","volume":"18","author":"GH Jackson","year":"2021","unstructured":"Jackson GH, Pawlyn C, Cairns DA, et al. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): interim analysis of an open-label randomised controlled trial. PLoS Med. 2021;18(1):e1003454.","journal-title":"PLoS Med"},{"issue":"11","key":"55_CR13","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810\u201321.","journal-title":"Lancet Haematol"},{"issue":"8","key":"55_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"2","key":"55_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","volume":"31","author":"H Ludwig","year":"2013","unstructured":"Ludwig H, Viterbo L, Greil R, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013;31(2):247\u201355.","journal-title":"J Clin Oncol"},{"issue":"10","key":"55_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906\u201317.","journal-title":"N Engl J Med"},{"issue":"19","key":"55_CR17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759\u201369.","journal-title":"N Engl J Med"},{"issue":"5","key":"55_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-022-01631-8","volume":"57","author":"D Karam","year":"2022","unstructured":"Karam D, Gertz M, Lacy M, et al. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplant. 2022;57(5):803\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"55_CR19","doi-asserted-by":"publisher","first-page":"e734","DOI":"10.1016\/j.clml.2020.05.027","volume":"20","author":"S Leng","year":"2020","unstructured":"Leng S, Moshier E, Tremblay D, et al. Timing of autologous stem cell transplantation for multiple myeloma in the era of current therapies. Clin Lymphoma Myeloma Leuk. 2020;20(10):e734\u201351.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"55_CR20","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495\u2013502.","journal-title":"N Engl J Med"},{"issue":"17","key":"55_CR21","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434\u201341.","journal-title":"J Clin Oncol"},{"issue":"5","key":"55_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.13994","volume":"173","author":"EK Mai","year":"2016","unstructured":"Mai EK, Benner A, Bertsch U, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173(5):731\u201341.","journal-title":"Br J Haematol"},{"issue":"7","key":"55_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589\u201397.","journal-title":"J Clin Oncol"},{"issue":"6","key":"55_CR24","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456\u201368.","journal-title":"Lancet Haematol"},{"issue":"19","key":"55_CR25","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782\u201391.","journal-title":"N Engl J Med"},{"issue":"19","key":"55_CR26","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770\u201381.","journal-title":"N Engl J Med"},{"issue":"10","key":"55_CR27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895\u2013905.","journal-title":"N Engl J Med"},{"issue":"9","key":"55_CR28","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431\u201342.","journal-title":"Lancet Haematol"},{"issue":"1","key":"55_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57\u201373.","journal-title":"Lancet Oncol"},{"issue":"10168","key":"55_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253\u201364.","journal-title":"Lancet"},{"issue":"10","key":"55_CR31","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1378\u201390.","journal-title":"Lancet Oncol"},{"issue":"5","key":"55_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.clml.2020.12.021","volume":"21","author":"AS Rosenberg","year":"2021","unstructured":"Rosenberg AS, Facon T, Parikh K, et al. Association of morbid progression with overall survival among patients with multiple myeloma: validation of the progression-free survival endpoint. Clin Lymphoma Myeloma Leuk. 2021;21(5):345-354 e344.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"55_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2022007082","volume":"7","author":"S Goldman-Mazur","year":"2023","unstructured":"Goldman-Mazur S, Visram A, Kapoor P, et al. Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Adv. 2023;7(6):909\u201317.","journal-title":"Blood Adv"},{"issue":"4","key":"55_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.25415","volume":"94","author":"R Chakraborty","year":"2019","unstructured":"Chakraborty R, Liu HD, Rybicki L, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019;94(4):439\u201345.","journal-title":"Am J Hematol"},{"issue":"12","key":"55_CR35","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41409-022-01818-z","volume":"57","author":"SH Jung","year":"2022","unstructured":"Jung SH, Min CK, Lee JH, et al. Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909). Bone Marrow Transplant. 2022;57(12):1797\u2013802.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"55_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/bmt.2012.151","volume":"48","author":"D Zamarin","year":"2013","unstructured":"Zamarin D, Giralt S, Landau H, et al. Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients\u2019 monitoring after transplantation. Bone Marrow Transplant. 2013;48(3):419\u201324.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"55_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4149\/neo_2018_170519N363","volume":"65","author":"M Stork","year":"2018","unstructured":"Stork M, Sevcikova S, Adam Z, et al. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. Neoplasma. 2018;65(4):585\u201391.","journal-title":"Neoplasma"},{"issue":"1","key":"55_CR38","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1002\/hsr2.104","volume":"2","author":"C Hulin","year":"2019","unstructured":"Hulin C, de la Rubia J, Dimopoulos MA, et al. Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. Health science reports. 2019;2(1):e104.","journal-title":"Health science reports"},{"issue":"3","key":"55_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.14086","volume":"177","author":"Y Reyal","year":"2017","unstructured":"Reyal Y, Popat R, Cheesman S, et al. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse. Br J Haematol. 2017;177(3):495\u20137.","journal-title":"Br J Haematol"},{"issue":"23","key":"55_CR40","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1182\/blood.V126.23.5387.5387","volume":"126","author":"W Wu","year":"2015","unstructured":"Wu W, Zheng G, Han X, Zhao Y, et al. Efficacy and safety of bortezomib based regimens retreatment in relapsed multiple myeloma patients: results from a retrospective study. Blood. 2015;126(23):5387.","journal-title":"Blood."},{"issue":"7","key":"55_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1179\/1607845414Y.0000000218","volume":"20","author":"A Oriol","year":"2015","unstructured":"Oriol A, Giraldo P, Kotsianidis I, et al. Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study. Hematology. 2015;20(7):405\u20139.","journal-title":"Hematology"},{"key":"55_CR42","first-page":"w13562","volume":"142","author":"C Taverna","year":"2012","unstructured":"Taverna C, Voegeli J, Trojan A, Olie RA, von Rohr A. Effective response with bortezomib retreatment in relapsed multiple myeloma\u2013a multicentre retrospective survey in Switzerland. Swiss Med Wkly. 2012;142:w13562.","journal-title":"Swiss Med Wkly"},{"issue":"3\u20134","key":"55_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000322866","volume":"79","author":"I Hrusovsky","year":"2010","unstructured":"Hrusovsky I, Emmerich B, von Rohr A, et al. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology. 2010;79(3\u20134):247\u201354.","journal-title":"Oncology"},{"issue":"5","key":"55_CR44","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12198","volume":"160","author":"MT Petrucci","year":"2013","unstructured":"Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013;160(5):649\u201359.","journal-title":"Br J Haematol"},{"issue":"10","key":"55_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ajh.21517","volume":"84","author":"R Sood","year":"2009","unstructured":"Sood R, Carloss H, Kerr R, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol. 2009;84(10):657\u201360.","journal-title":"Am J Hematol"},{"issue":"23","key":"55_CR46","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood.V126.23.3051.3051","volume":"126","author":"A Chari","year":"2015","unstructured":"Chari A, Cho HJ, Parekh S, et al. Recapturing disease response: a phase II study of high dose carfilzomib in patients with relapsed or refractory multiple myeloma who have progressed on standard dose carfilzomib. Blood. 2015;126(23):3051.","journal-title":"Blood"},{"issue":"19","key":"55_CR47","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"55_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"17","key":"55_CR49","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334.","journal-title":"N Engl J Med"},{"issue":"14","key":"55_CR50","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"55_CR51","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med"},{"issue":"9","key":"55_CR52","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","volume":"21","author":"J Lu","year":"2021","unstructured":"Lu J, Fu W, Li W, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study. Clin Lymphoma Myeloma Leuk. 2021;21(9):e699\u2013709.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"55_CR53","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394.","journal-title":"Lancet Oncol"},{"issue":"10245","key":"55_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186\u201397.","journal-title":"Lancet"},{"issue":"10214","key":"55_CR55","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107.","journal-title":"Lancet"},{"issue":"10292","key":"55_CR56","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"issue":"10262","key":"55_CR57","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563\u201373.","journal-title":"Lancet"},{"issue":"6","key":"55_CR58","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801\u201312.","journal-title":"Lancet Oncol"},{"issue":"23","key":"55_CR59","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","volume":"127","author":"A Jakubowiak","year":"2016","unstructured":"Jakubowiak A, Offidani M, P\u00e9gourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM. Blood. 2016;127(23):2833\u201340.","journal-title":"Blood"},{"issue":"2","key":"55_CR60","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"55_CR61","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953\u201364.","journal-title":"Lancet Oncol."},{"issue":"15","key":"55_CR62","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-19-1997","volume":"26","author":"S Ailawadhi","year":"2020","unstructured":"Ailawadhi S, Sexton R, Lentzsch S, et al. Low-dose versus high-dose carfilzomib with dexamethasone (S1304) in patients with relapsed-refractory multiple myeloma. Clin Cancer Res. 2020;26(15):3969\u201378.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"55_CR63","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055\u201366.","journal-title":"Lancet Oncol"},{"issue":"7","key":"55_CR64","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"21","key":"55_CR65","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133\u201342.","journal-title":"N Engl J Med"},{"issue":"21","key":"55_CR66","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"24","key":"55_CR67","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"12","key":"55_CR68","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20(12):1760\u201372.","journal-title":"Lancet Oncol"},{"issue":"1","key":"55_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5045\/br.2021.2021176","volume":"57","author":"SI Kim","year":"2022","unstructured":"Kim SI, Jung SH, Yhim HY, et al. Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. Blood Res. 2022;57(1):51\u20138.","journal-title":"Blood Res"},{"issue":"5","key":"55_CR70","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12185-014-1672-1","volume":"100","author":"SH Jung","year":"2014","unstructured":"Jung SH, Kang SJ, Jang HC, et al. Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens. Int J Hematol. 2014;100(5):473\u20137.","journal-title":"Int J Hematol"},{"issue":"6","key":"55_CR71","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","volume":"100","author":"MM Oken","year":"1996","unstructured":"Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100(6):624\u20138.","journal-title":"Am J Med"},{"issue":"12","key":"55_CR72","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/leu.2012.124","volume":"26","author":"DH Vesole","year":"2012","unstructured":"Vesole DH, Oken MM, Heckler C, et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study. Leukemia. 2012;26(12):2517\u201320.","journal-title":"Leukemia"},{"issue":"1","key":"55_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2141.2012.09233.x","volume":"159","author":"J Minarik","year":"2012","unstructured":"Minarik J, Pika T, Bacovsky J, Langova K, Scudla V. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol. 2012;159(1):111\u20133.","journal-title":"Br J Haematol"},{"issue":"12","key":"55_CR74","first-page":"5437","volume":"32","author":"T Fukushima","year":"2012","unstructured":"Fukushima T, Sato T, Nakamura T, et al. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res. 2012;32(12):5437\u201340.","journal-title":"Anticancer Res"},{"issue":"3","key":"55_CR75","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jjco\/hyq194","volume":"41","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol. 2011;41(3):353\u20137.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"55_CR76","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/cncr.24006","volume":"115","author":"E Vickrey","year":"2009","unstructured":"Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115(1):229\u201332.","journal-title":"Cancer"},{"issue":"4","key":"55_CR77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.suponc.2011.10.006","volume":"10","author":"A Swaika","year":"2012","unstructured":"Swaika A, Paulus A, Miller KC, et al. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012;10(4):155\u20139.","journal-title":"J Support Oncol"},{"issue":"10","key":"55_CR78","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289\u201394.","journal-title":"Blood"},{"issue":"2","key":"55_CR79","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02698044","volume":"24","author":"A Avil\u00e9s","year":"2007","unstructured":"Avil\u00e9s A, Nambo MJ, Neri N, Casta\u00f1eda C, Cleto S, Huerta-Guzm\u00e1n J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24(2):227\u201330.","journal-title":"Med Oncol"},{"issue":"1","key":"55_CR80","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.3747\/co.20.1055","volume":"20","author":"A Avil\u00e9s","year":"2013","unstructured":"Avil\u00e9s A, Neri N, Huerta-Guzm\u00e1n J, Nambo MJ. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol. 2013;20(1):e13-20.","journal-title":"Curr Oncol"},{"issue":"2","key":"55_CR81","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"JR Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593\u2013602.","journal-title":"J Clin Oncol."},{"issue":"2","key":"55_CR82","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","volume":"101","author":"H Brincker","year":"1998","unstructured":"Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. Br J Haematol. 1998;101(2):280\u20136.","journal-title":"Br J Haematol."},{"issue":"9","key":"55_CR83","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","volume":"100","author":"R Garc\u00eda-Sanz","year":"2015","unstructured":"Garc\u00eda-Sanz R, Oriol A, Moreno MJ, et al. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 2015;100(9):1207\u201313.","journal-title":"Haematologica"},{"key":"55_CR84","first-page":"113","volume":"57 Suppl","author":"M Kraj","year":"2000","unstructured":"Kraj M, Pog\u0142\u00f3d R, Pawlikowski J, Maj S, Nasi\u0142owska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Acta Pol Pharm. 2000;57 Suppl:113\u20136.","journal-title":"Acta Pol Pharm."},{"issue":"9","key":"55_CR85","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3109\/10428190309178778","volume":"44","author":"P Musto","year":"2003","unstructured":"Musto P, Falcone A, Sanpaolo G, et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma. 2003;44(9):1545\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"55_CR86","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/cncr.23783","volume":"113","author":"P Musto","year":"2008","unstructured":"Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7):1588\u201395.","journal-title":"Cancer"},{"issue":"3","key":"55_CR87","first-page":"101","volume":"33","author":"A Bilici","year":"2010","unstructured":"Bilici A, Ustaalioglu BB, Gumus M, et al. Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer? Onkologie. 2010;33(3):101\u20135.","journal-title":"Onkologie"},{"issue":"5","key":"55_CR88","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","volume":"65","author":"E Terpos","year":"2000","unstructured":"Terpos E, Palermos J, Tsionos K, et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol. 2000;65(5):331\u20136.","journal-title":"Eur J Haematol"},{"issue":"3","key":"55_CR89","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381.","journal-title":"Lancet Oncol"},{"issue":"19","key":"55_CR90","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, et al. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384\u201390.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"55_CR91","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","volume":"23","author":"JE McDonald","year":"2017","unstructured":"McDonald JE, Kessler MM, Gardner MW, et al. Assessment of total lesion glycolysis by (18)F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23(8):1981\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"55_CR92","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","volume":"103","author":"FE Davies","year":"2018","unstructured":"Davies FE, Rosenthal A, Rasche L, et al. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018;103(6):1047\u201353.","journal-title":"Haematologica"},{"issue":"1","key":"55_CR93","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00259-018-4114-0","volume":"46","author":"SH Jung","year":"2019","unstructured":"Jung SH, Kwon SY, Min JJ, et al. (18)F-FDG PET\/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the revised international staging system. Eur J Nucl Med Mol Imaging. 2019;46(1):107\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"55_CR94","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3348\/kjr.2018.19.3.481","volume":"19","author":"SH Moon","year":"2018","unstructured":"Moon SH, Choi WH, Yoo IR, et al. Prognostic value of baseline (18)F-Fluorodeoxyglucose PET\/CT in patients with multiple myeloma: a multicenter cohort study. Korean J Radiol. 2018;19(3):481\u20138.","journal-title":"Korean J Radiol"},{"issue":"12","key":"55_CR95","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.25279","volume":"93","author":"MA Aljama","year":"2018","unstructured":"Aljama MA, Sidiqi MH, Buadi FK, et al. Utility and prognostic value of (18) F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018;93(12):1518\u201323.","journal-title":"Am J Hematol"},{"issue":"6","key":"55_CR96","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00259-019-4275-5","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Narita K, Kobayashi H, et al. Pretreatment (18)F-FDG PET\/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46(6):1325\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"55_CR97","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clml.2021.08.012","volume":"22","author":"HJ Cho","year":"2022","unstructured":"Cho HJ, Baek DW, Kim JH, et al. Favorable long-term outcomes with autologous stem cell transplantation for high-risk multiple myeloma patients with a positive result on (18)F-FDG PET\/CT at baseline. Clin Lymphoma Myeloma Leuk. 2022;22(2):113\u201320.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"55_CR98","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41408-021-00577-2","volume":"11","author":"HJ Cho","year":"2021","unstructured":"Cho HJ, Jung SH, Jo JC, et al. Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET\/CT. Blood Cancer J. 2021;11(12):190.","journal-title":"Blood Cancer J"},{"issue":"1","key":"55_CR99","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-021-00846-y","volume":"11","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Merz M, Raab MS, et al. The prognostic significance of [(18)F]FDG PET\/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11(1):100.","journal-title":"EJNMMI Res"},{"issue":"1","key":"55_CR100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","volume":"132","author":"L Rasche","year":"2018","unstructured":"Rasche L, Angtuaco EJ, Alpe TL, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132(1):59\u201366.","journal-title":"Blood"},{"issue":"4","key":"55_CR101","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/RLU.0000000000000696","volume":"40","author":"R Fonti","year":"2015","unstructured":"Fonti R, Pace L, Cerchione C, et al. 18F-FDG PET\/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med. 2015;40(4):303\u20138.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"55_CR102","doi-asserted-by":"publisher","first-page":"300","DOI":"10.12701\/jyms.2021.01648","volume":"39","author":"JM Lee","year":"2022","unstructured":"Lee JM, Cho HJ, Moon JH, Sohn SK, Park B, Baek DW. Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study. J Yeungnam Med Sci. 2022;39(4):300\u20138.","journal-title":"J Yeungnam Med Sci"},{"issue":"4","key":"55_CR103","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00330-020-07295-6","volume":"31","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang Q, Wu X, et al. Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma. Eur Radiol. 2021;31(4):1843\u201352.","journal-title":"Eur Radiol"},{"issue":"6","key":"55_CR104","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3324\/haematol.2015.124115","volume":"100","author":"EK Mai","year":"2015","unstructured":"Mai EK, Hielscher T, Kloth JK, et al. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica. 2015;100(6):818\u201325.","journal-title":"Haematologica"},{"issue":"1","key":"55_CR105","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000370235","volume":"134","author":"MK Song","year":"2015","unstructured":"Song MK, Chung JS, Lee JJ, et al. Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Acta Haematol. 2015;134(1):7\u201316.","journal-title":"Acta Haematol"},{"issue":"6","key":"55_CR106","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.12820","volume":"165","author":"MK Song","year":"2014","unstructured":"Song MK, Chung JS, Lee JJ, et al. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. Br J Haematol. 2014;165(6):777\u201385.","journal-title":"Br J Haematol"},{"issue":"10","key":"55_CR107","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068\u201376.","journal-title":"Blood"},{"issue":"9","key":"55_CR108","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","volume":"25","author":"R Walker","year":"2007","unstructured":"Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25(9):1121\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"55_CR109","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdi362","volume":"16","author":"LA Moulopoulos","year":"2005","unstructured":"Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol. 2005;16(11):1824\u20138.","journal-title":"Ann Oncol"},{"issue":"9","key":"55_CR110","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ajh.23258","volume":"87","author":"LA Moulopoulos","year":"2012","unstructured":"Moulopoulos LA, Dimopoulos MA, Kastritis E, et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol. 2012;87(9):861\u20134.","journal-title":"Am J Hematol"},{"issue":"4","key":"55_CR111","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","volume":"23","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty R, Muchtar E, Kumar SK, et al. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biol Blood Marrow Transplant. 2017;23(4):598\u2013605.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"55_CR112","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.18211","volume":"198","author":"H Cho","year":"2022","unstructured":"Cho H, Shin S, Chung H, et al. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma. Br J Haematol. 2022;198(3):503\u201314.","journal-title":"Br J Haematol"},{"issue":"12","key":"55_CR113","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41409-018-0241-2","volume":"53","author":"CA Clark","year":"2018","unstructured":"Clark CA, Mosse CA, Chen H, et al. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. Bone Marrow Transplant. 2018;53(12):1589\u201392.","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"55_CR114","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood.V128.22.245.245","volume":"128","author":"RM de Tute","year":"2016","unstructured":"de Tute RM, Rawstron AC, Cairns DA, et al. Impact of minimal residual disease in transplant ineligible myeloma patients: results from the UK NCRI myeloma XI Trial. Blood. 2016;128(22):245.","journal-title":"Blood"},{"issue":"25","key":"55_CR115","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889\u2013900.","journal-title":"J Clin Oncol"},{"issue":"9","key":"55_CR116","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","volume":"8","author":"BA Derman","year":"2022","unstructured":"Derman BA, Kansagra A, Zonder J, et al. Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study. JAMA Oncol. 2022;8(9):1278\u201386.","journal-title":"JAMA Oncol"},{"issue":"18","key":"55_CR117","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953\u201363.","journal-title":"Blood"},{"issue":"5","key":"55_CR118","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","volume":"125","author":"M Gambella","year":"2019","unstructured":"Gambella M, Omed\u00e9 P, Spada S, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer. 2019;125(5):750\u201360.","journal-title":"Cancer"},{"issue":"3","key":"55_CR119","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","volume":"25","author":"TE Hahn","year":"2019","unstructured":"Hahn TE, Wallace PK, Fraser R, et al. Minimal residual disease (MRD) assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) study. Biol Blood Marrow Transplant. 2019;25(3):S4\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"55_CR120","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3343\/alm.2022.42.5.558","volume":"42","author":"HY Kim","year":"2022","unstructured":"Kim HY, Yoo IY, Lim DJ, et al. Clinical utility of next-generation flow-based minimal residual disease assessment in patients with multiple myeloma. Ann Lab Med. 2022;42(5):558\u201365.","journal-title":"Ann Lab Med"},{"issue":"2","key":"55_CR121","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41409-021-01532-2","volume":"57","author":"R LeBlanc","year":"2022","unstructured":"LeBlanc R, Ahmad I, Terra R, et al. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous\/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplant. 2022;57(2):252\u201360.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"55_CR122","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00277-019-03609-x","volume":"98","author":"H Li","year":"2019","unstructured":"Li H, Li F, Zhou X, et al. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. Ann Hematol. 2019;98(5):1185\u201395.","journal-title":"Ann Hematol"},{"issue":"6","key":"55_CR123","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/leu.2017.58","volume":"31","author":"J Martinez-Lopez","year":"2017","unstructured":"Martinez-Lopez J, Sanchez-Vega B, Barrio S, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia. 2017;31(6):1446\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"55_CR124","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"55_CR125","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.18632\/oncotarget.12641","volume":"8","author":"S Oliva","year":"2017","unstructured":"Oliva S, Gambella M, Gilestro M, et al. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget. 2017;8(4):5924\u201335.","journal-title":"Oncotarget"},{"issue":"6","key":"55_CR126","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Dimopoulos MA, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141(6):579\u201391.","journal-title":"Blood"},{"issue":"6","key":"55_CR127","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41409-020-0791-y","volume":"55","author":"DA Patel","year":"2020","unstructured":"Patel DA, Gopalakrishnan R, Engelhardt BG, et al. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplant. 2020;55(6):1137\u201346.","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"55_CR128","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456\u201364.","journal-title":"Blood"},{"issue":"3","key":"55_CR129","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/cyto.b.21755","volume":"96","author":"G Rossi","year":"2019","unstructured":"Rossi G, Falcone AP, Minervini MM, et al. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Cytometry B Clin Cytom. 2019;96(3):195\u2013200.","journal-title":"Cytometry B Clin Cytom"},{"issue":"22","key":"55_CR130","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1182\/blood.V128.22.3283.3283","volume":"128","author":"B Sanchez-Vega","year":"2016","unstructured":"Sanchez-Vega B, Alonso R, Cuenca I, et al. Prognostic impact of molecular response assessed by next-generation sequencing in a large cohort of multiple myeloma patients. Blood. 2016;128(22):3283.","journal-title":"Blood"},{"issue":"8","key":"55_CR131","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.3324\/haematol.2017.165217","volume":"102","author":"C Schinke","year":"2017","unstructured":"Schinke C, Hoering A, Wang H, et al. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017;102(8):e313\u20136.","journal-title":"Haematologica"},{"key":"55_CR132","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1182\/blood-2018-99-112790","volume":"132","author":"MV Solovev","year":"2018","unstructured":"Solovev MV, Mendeleeva LP, Firsova MV, et al. Efficacy of maintenance therapy following auto-HSCT depending on MRD status in patients with multiple myeloma. Blood. 2018;132:3432.","journal-title":"Blood"},{"key":"55_CR133","doi-asserted-by":"publisher","first-page":"820605","DOI":"10.3389\/fonc.2022.820605","volume":"12","author":"R Turner","year":"2022","unstructured":"Turner R, Kalff A, Bergin K, Gorniak M, Fleming S, Spencer A. The utility of Euroflow MRD assessment in real-world multiple myeloma practice. Front Oncol. 2022;12:820605.","journal-title":"Front Oncol"},{"key":"55_CR134","first-page":"2018","volume":"215626","author":"MPC Austin","year":"2018","unstructured":"Austin MPC, Woods H. Sustained MRD negativity at 12 months post-ASCT predicts outcomes for myeloma patients: a real world study. EHA Libr. 2018;215626:2018.","journal-title":"EHA Libr"},{"issue":"15","key":"55_CR135","first-page":"Suppl","volume":"37","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, et al. Efficacy of daratumumab (DARA) + bortezomib\/thalidomide\/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: analysis of the CASSIOPEIA trial. Am Soc Clin Oncol. 2019;37(15):Suppl.","journal-title":"Am Soc Clin Oncol."},{"issue":"Supplement_1","key":"55_CR136","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood-2019-123426","volume":"134","author":"N Bahlis","year":"2019","unstructured":"Bahlis N, Facon T, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant: updated analysis of Maia. Blood. 2019;134(Supplement_1):1875.","journal-title":"Blood"},{"issue":"12","key":"55_CR137","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","volume":"24","author":"J Gu","year":"2018","unstructured":"Gu J, Liu J, Chen M, Huang B, Li J. Longitudinal flow cytometry identified \u201cminimal residual disease\u201d (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma. Biol Blood Marrow Transplant. 2018;24(12):2568\u201374.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"55_CR138","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J. 2021;11(6):106.","journal-title":"Blood Cancer J"},{"issue":"8","key":"55_CR139","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"55_CR140","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438\u201347.","journal-title":"N Engl J Med"},{"issue":"13","key":"55_CR141","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","volume":"25","author":"TA Brighton","year":"2019","unstructured":"Brighton TA, Khot A, Harrison SJ, et al. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clin Cancer Res. 2019;25(13):3772\u20135.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"55_CR142","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126\u201337.","journal-title":"J Clin Oncol"},{"issue":"12","key":"55_CR143","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548.","journal-title":"Lancet Oncol"},{"key":"55_CR144","first-page":"1","volume":"40","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Dhodapkar MV, Lonial S. The role of early intervention in high-risk smoldering myeloma. Am Soc Clin Oncol Educ Book. 2020;40:1\u20139.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"55_CR145","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","volume":"174","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Hern\u00e1ndez MT, Salvador C, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur J Cancer. 2022;174:243\u201350.","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1007\/s44313-025-00074-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000}}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00055-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00055-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:09:30Z","timestamp":1744218570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00055-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00055-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s44313-025-00074-6","asserted-by":"object"}]},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s44313-025-00074-6","URL":"https:\/\/doi.org\/10.1007\/s44313-025-00074-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}